September 27, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Chimerix announces closing of brincidofovir sale to Emergent BioSolutions

TOKYO, Japan, September 27, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio" or the “Company”) today announced that Chimerix, Inc. (Headquarters: Durham, North
Carolina, "Chimerix") announced in a press release dated September 26, 2022 (EST) that it hascompleted the closing of the sale of its antiviral product brincidofovir ("BCV") to Emergent BioSolutions
Inc. (Headquarters: Gaithersburg, Maryland, "Emergent").
Please refer to Chimerix website for details of the press release.
https://ir.chimerix.com/press-releases
All rights and obligations of Chimerix under the license agreement between SymBio and Chimerix
effective as of September 30, 2019 will be assigned to Emergent. The Company’s exclusive worldwide
development, manufacturing, and marketing rights for BCV for all indications except the prevention
and treatment of orthopox infections will not be affected.
The Company does not expect the information presented herein to have any material impact on its
financial outlook for the fiscal year ending December 2022.

1

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About Anti-viral Drug Brincidofovir
Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved
and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits
not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is
expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses
such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus,papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that canreduce the risk of nephrotoxicity, which is a serious side effect of CDV.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (NYSE: EBS) is a pharmaceutical company based in Gaithersburg,Maryland, USA. The company develops vaccines and antibody drugs against infectious diseases andopioid overdose, and provides medical devices for biodefense. The company's mission is to protect andenrich lives, protecting people from things they hope will never happen and preparing them for theeventuality that they do happen for over 20 years. Through its portfolio of vaccines and therapeutics
developed and manufactured for governments and consumers, the company provides solutions tocomplex and urgent public health threats. The company also provides comprehensive contractdevelopment and manufacturing services to pharmaceutical and biotechnology companies.
For more information, visit Emergent website at https://www.emergentbiosolutions.com).
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously
served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May
2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc.
(Headquarters: Durham, North Carolina, President: Carolyn Yanavich).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

2